. Ics-glossary,

. Ics.-disponible and . Sur,

P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier et al., The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society, Am J Obstet Gynecol. juill, vol.187, issue.1, pp.116-142, 2002.

F. Haab, G. Amarenco, P. Coloby, P. Grise, B. Jacquetin et al.,

, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol. déc, vol.14, issue.6, pp.1103-1114, 2004.

W. F. Stewart, J. B. Van-rooyen, G. W. Cundiff, P. Abrams, A. R. Herzog et al., Prevalence and burden of overactive bladder in the United States, World J Urol. mai, vol.20, issue.6, pp.327-363, 2003.

D. E. Irwin, I. Milsom, S. Hunskaar, K. Reilly, Z. Kopp et al., Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study, Eur Urol. déc, vol.50, issue.6, pp.1306-1320, 2006.

A. Wennberg, U. Molander, M. Fall, C. Edlund, R. Peeker et al., A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women, Eur Urol. avr, vol.55, issue.4, pp.783-91, 2009.

J. Cornu, G. Amarenco, F. Bruyere, E. Chartier-kastler, B. Fatton et al., Prevalence and initial management of overactive bladder in France: A cross-sectional study

, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol. juin, vol.26, issue.7, pp.415-439, 2016.

I. Milsom, K. S. Coyne, S. Nicholson, M. Kvasz, C. Chen et al., Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review, Eur Urol. 1 janv, vol.65, issue.1, pp.79-95, 2014.

D. E. Irwin, Z. S. Kopp, B. Agatep, I. Milsom, and P. Abrams, Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction, BJU Int, vol.108, issue.7, pp.1132-1140, 2011.

S. Bartoli, G. Aguzzi, and R. Tarricone, Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review, Urology. mars, vol.75, issue.3, pp.491-500, 2010.

K. S. Coyne, C. C. Sexton, C. L. Thompson, J. Q. Clemens, C. I. Chen et al., Impact of overactive bladder on work productivity, Urology. juill, vol.80, issue.1, pp.97-103, 2012.

C. C. Sexton, K. S. Coyne, V. Vats, Z. S. Kopp, D. E. Irwin et al., Impact of overactive bladder on work productivity in the United States: results from EpiLUTS, Am J Manag Care. mars, vol.15, issue.4, pp.98-107, 2009.

P. Mandpe and B. Prabhakar, Pathophysiology, mechanism and management of overactive bladder syndroma review, Int J Pharm Pharm Sci. 1 juill, vol.10, issue.7, p.1, 2018.

G. Mcmurray, N. Dass, and A. F. Brading, Purinoceptor subtypes mediating contraction and relaxation of marmoset urinary bladder smooth muscle, Br J Pharmacol. avr, vol.123, issue.8, pp.1579-86, 1998.

L. A. Birder and W. C. De-groat, Mechanisms of disease: involvement of the urothelium in bladder dysfunction, Nat Clin Pract Urol. janv, vol.4, issue.1, pp.46-54, 2007.

B. Schurch, M. Stöhrer, G. Kramer, D. M. Schmid, G. Gaul et al., Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results, J Urol. sept, vol.164, issue.3, pp.692-699, 2000.

F. Cruz, Targets for botulinum toxin in the lower urinary tract, Neurourol Urodyn. janv, vol.33, issue.1, pp.31-39, 2014.

V. M. Collins, D. M. Daly, M. Liaskos, N. G. Mckay, D. Sellers et al., OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium, BJU Int, vol.112, issue.7, pp.1018-1044, 2013.

A. Apostolidis, R. Popat, Y. Yiangou, D. Cockayne, A. Ford et al., Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J Urol. sept, vol.174, issue.3, pp.977-82, 2005.

L. L. Subak, R. Wing, D. S. West, F. Franklin, E. Vittinghoff et al., Weight loss to treat urinary incontinence in overweight and obese women, N Engl J Med. 29 janv, vol.360, issue.5, pp.481-90, 2009.

K. A. Said, Y. Leroux, B. Menahem, A. Doerfler, A. Alves et al., Effet de la chirurgie bariatrique sur l'incontinence urinaire et fécale chez les sujets obèses, Prog En Urol, vol.26, issue.13, p.805, 2016.

H. Hashim and P. Abrams, How should patients with an overactive bladder manipulate their fluid intake?, BJU Int. juill, vol.102, issue.1, pp.62-68, 2008.

, EAU-Guidelines-Urinary-Incontinence-2015.pdf [Internet]. Disponible sur

C. M. Bryant, C. J. Dowell, and G. Fairbrother, Caffeine reduction education to improve urinary symptoms, Br J Nurs Mark Allen Publ. 25 mai, vol.11, issue.8, pp.560-565, 2002.

N. N. Maserejian, C. G. Wager, E. L. Giovannucci, T. M. Curto, K. T. Mcvary et al., Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women, Am J Epidemiol. 15 juin, vol.177, issue.12, pp.1399-410, 2013.

H. M. Dallosso, C. W. Mcgrother, R. J. Matthews, and M. Donaldson, Leicestershire MRC Incontinence Study Group. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women, BJU Int. juill, vol.92, issue.1, pp.69-77, 2003.

N. Turmel, C. Hentzen, C. Chesnel, A. Charlannes, L. Breton et al., Alimentation, régimes et diététique dans le syndrome clinique d'hyperactivité vésicale : revue de la littérature, Prog En Urol Elsevier Masson. juin, vol.27, issue.7, pp.395-401, 2017.

. De, AFU -Chapitre 07 -Incontinence urinaire de l'adulte et du sujet âgé

S. Kaya, T. Akbayrak, and S. Beksaç, Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial, Clin Rehabil. avr, vol.25, issue.4, pp.327-365, 2011.

A. Mattiasson, A. Masala, R. Morton, J. Bolodeoku, . Solar-study et al., Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study, BJU Int. avr, vol.105, issue.8, pp.1126-1161, 2010.

C. C. Sexton, S. M. Notte, C. Maroulis, R. R. Dmochowski, L. Cardozo et al., Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature, Int J Clin Pract. mai, vol.65, issue.5, pp.567-85, 2011.

G. Nabi, J. D. Cody, G. Ellis, P. Herbison, and J. Hay-smith, Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev, p.3781, 2006.

P. Madhuvrata, Which anticholinergic drug for overactive bladder symptoms in adults, 2012.

M. S. Mcdonagh, D. Selover, J. Santa, and S. Thakurta, Drug Class Review: Agents for Overactive Bladder: Final Report Update 4

. Portland, Oregon Health & Science University, 2009.

P. Herbison and J. E. Mckenzie, Which anticholinergic is best for people with overactive bladders? A network meta-analysis, Neurourol Urodyn. 1 févr, vol.38, issue.2, pp.525-559, 2019.

, Overview | Urinary incontinence and pelvic organ prolapse in women: management | Guidance | NICE

G. Novara, A. Galfano, S. Secco, D. 'elia, C. Cavalleri et al., A systematic review and metaanalysis of randomized controlled trials with antimuscarinic drugs for overactive bladder, Eur Urol, vol.54, issue.4, pp.740-63, 2008.

X. Deffieux, T. Thubert, G. Demoulin, A. Rivain, E. Faivre et al., EMC -Incontinence urinaire de la femme

G. Kay, T. Crook, L. Rekeda, R. Lima, U. Ebinger et al., Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects, Eur Urol. août, vol.50, issue.2, pp.317-343, 2006.

, Prévenir la iatrogénèse médicamenteuse chez le sujet âgé, AFSSAPS, vol.12, 2005.

W. M. White, R. B. Pickens, R. Doggweiler, and F. A. Klein, Short-Term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in the Elderly Population, J Urol. 1 déc, vol.180, issue.6, pp.2522-2528, 2008.

V. W. Nitti, V. Khullar, P. Van-kerrebroeck, S. Herschorn, J. Cambronero et al., Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies, Int J Clin Pract. juill, vol.67, issue.7, pp.619-651, 2013.

C. R. Chapple, V. Dvorak, P. Radziszewski, P. Van-kerrebroeck, J. J. Wyndaele et al., A phase II dose-ranging study of mirabegron in patients with overactive bladder, Int Urogynecology J. sept, vol.24, issue.9, pp.1447-58, 2013.

, BETMIGA (mirabegron), antispasmodique urinaire

. Haute-autorité-de-santé and . Disponible,

S. Herschorn, C. R. Chapple, P. Abrams, S. Arlandis, D. Mitcheson et al., Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study), BJU Int, vol.120, issue.4, pp.562-75, 2017.

P. Abrams, C. Kelleher, D. Staskin, T. Rechberger, R. Kay et al., Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony), Eur Urol. mars, vol.67, issue.3, pp.577-88, 2015.

D. Robinson, C. Kelleher, D. Staskin, E. R. Mueller, C. Falconer et al., Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients, Neurourol Urodyn, vol.37, issue.1, pp.394-406, 2018.

I. Ramírez-garcía, L. Blanco-ratto, S. Kauffmann, A. Carralero-martínez, and E. Sánchez, Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial, Neurourol Urodyn. janv, vol.38, issue.1, pp.261-269, 2019.

J. Booth, L. Connelly, S. Dickson, F. Duncan, and M. Lawrence, The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review, Neurourol Urodyn, vol.37, issue.2, pp.528-569, 2018.

P. O. Bellette, P. C. Rodrigues-palma, V. Hermann, C. Riccetto, M. Bigozzi et al.,

, Actas Urol Esp. janv, vol.33, issue.1, pp.58-63, 2009.

F. Stewart, L. F. Gameiro, E. Dib, R. Gameiro, M. O. Kapoor et al., Electrical stimulation with nonimplanted electrodes for overactive bladder in adults, Cochrane Database Syst Rev, vol.09, p.10098, 2016.

K. M. Peters, D. J. Carrico, R. A. Perez-marrero, A. U. Khan, L. S. Wooldridge et al., Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial, J Urol. avr, vol.183, issue.4, pp.1438-1481, 2010.

E. Finazzi-agrò, F. Petta, F. Sciobica, P. Pasqualetti, S. Musco et al., Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial, J Urol, vol.184, issue.5, pp.2001-2007, 2010.

W. Yoong, P. Shah, R. Dadswell, and L. Green, Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders, Int Urogynecology J. mai, vol.24, issue.5, pp.795-804, 2013.

O. Preyer, W. Umek, T. Laml, V. Bjelic-radisic, B. Gabriel et al., Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial, Eur J Obstet Gynecol Reprod Biol. août, vol.191, pp.51-57, 2015.

S. C. Souto, L. O. Reis, T. Palma, P. Palma, and F. Denardi, Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome, World J Urol. févr, vol.32, issue.1, pp.179-84, 2014.

B. C. Gill, J. Pizarro-berdichevsky, P. K. Bhattacharyya, T. S. Brink, B. K. Marks et al., Real-Time Changes in Brain Activity during Sacral Neuromodulation for Overactive Bladder, J Urol, vol.198, issue.6, pp.1379-85, 2017.

S. Siegel, K. Noblett, J. Mangel, T. L. Griebling, S. E. Sutherland et al., Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder, Neurourol Urodyn. mars, vol.34, issue.3, pp.224-254, 2015.

P. Van-kerrebroeck, A. C. Van-voskuilen, J. Heesakkers, A. Lycklama-Á-nijholt, S. Siegel et al., Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study, J Urol, vol.178, issue.5, pp.2029-2063, 2007.

A. Leroi, Y. Parc, P. Lehur, F. Mion, X. Barth et al., Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study, Ann Surg, vol.242, issue.5, pp.662-671, 2005.

A. S. El-azab and S. W. Siegel, Sacral neuromodulation for female pelvic floor disorders, Arab J Urol. mars, vol.17, issue.1, pp.14-22, 2019.

D. R. Greenberg, R. Syan, N. Young-lin, C. V. Comiter, and E. Enemchukwu, Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians, Neuromodulation J Int Neuromodulation Soc. 19 juin, 2019.

H. Tang, J. Chen, Y. Wang, T. Yu, C. Guo et al., Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial, Urol J. 6 sept, vol.11, issue.4, pp.1800-1805, 2014.

S. W. Siegel, F. Catanzaro, H. E. Dijkema, M. M. Elhilali, C. J. Fowler et al., Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgencyfrequency, and retention, Urology. 4 déc, vol.56, issue.6, pp.87-91, 2000.

C. Chapple, K. Sievert, S. Macdiarmid, V. Khullar, P. Radziszewski et al., OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial, Eur Urol. août, vol.64, issue.2, pp.249-56, 2013.

V. W. Nitti, R. Dmochowski, S. Herschorn, P. Sand, C. Thompson et al., OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial, J Urol. juin, vol.189, issue.6, pp.2186-93, 2013.

J. Hermieu, P. Ballanger, G. Amarenco, . Chartier-kastler-É, M. Cosson et al., Recommandations pour l'utilisation de la toxine botulinique de type A (Botox®) dans l'hyperactivité vésicale réfractaire idiopathique, Prog En Urol. déc, vol.23, issue.17, pp.1457-63, 2013.

, Haute Autorité de Santé -Commission de la transparence -19 novembre 2014 -BOTOX [Internet]. hassanté.fr

D. Sur,

A. Maurice-szamburski, N. Bruder, A. Loundou, X. Capdevila, and P. Auquier, Development and validation of a perioperative satisfaction questionnaire in regional anesthesia, Anesthesiology. janv, vol.118, issue.1, pp.78-87, 2013.

R. J. Feise, Do multiple outcome measures require p-value adjustment, BMC Med Res Methodol. 17 juin, vol.2, p.8, 2002.

M. J. Ratain and D. J. Sargent, Optimising the design of phase II oncology trials: the importance of randomisation, Eur J Cancer Oxf Engl, vol.45, issue.2, pp.275-80, 1990.

J. Moyson, F. Legrand, V. Bossche, M. Quackels, T. Roumeguère et al., Hyperactivité vésicale idiopathique : efficacité et tolérance des traitements pharmacologiques : revue de la littérature, Prog En Urol. mars, vol.27, issue.4, pp.203-231, 2017.

Q. Abdelmounaim, M. Asseban, K. Bazine, M. Najoui, J. Samir et al., Anticholinergiques et hyperactivité vésicale, Can Urol Assoc J. 14 janv, vol.8, issue.1-2, p.36, 2014.

K. Sievert, C. Chapple, S. Herschorn, M. Joshi, J. Zhou et al., OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder, Int J Clin Pract, vol.68, issue.10, pp.1246-56, 2014.

R. Dmochowski, C. Chapple, V. W. Nitti, M. Chancellor, K. Everaert et al., Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial, J Urol. déc, vol.184, issue.6, pp.2416-2438, 2010.

E. Rovner, M. Kennelly, H. Schulte-baukloh, J. Zhou, C. Haag-molkenteller et al., Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebocontrolled dose-finding study in idiopathic overactive bladder, Neurourol Urodyn. avr, vol.30, issue.4, pp.556-62, 2011.

C. J. Fowler, S. Auerbach, D. Ginsberg, D. Hale, P. Radziszewski et al., OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial, Eur Urol. juill, vol.62, issue.1, pp.148-57, 2012.

L. Brubaker, A. Gousse, P. Sand, C. Thompson, V. Patel et al., Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB, Int Urogynecology J. août, vol.23, issue.8, pp.1017-1042, 2012.

P. Denys, L. Normand, L. Ghout, I. Costa, P. Chartier-kastler et al., Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study, Eur Urol. mars, vol.61, issue.3, pp.520-529, 2012.

D. A. Ginsberg, M. J. Drake, A. Kaufmann, S. Radomski, A. E. Gousse et al., Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder, J Urol, vol.198, issue.4, pp.897-904, 2017.

V. W. Nitti, D. Ginsberg, K. Sievert, D. Sussman, S. Radomski et al., Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study, J Urol. sept, vol.196, issue.3, pp.791-800, 2016.

D. G. Tincello, S. Kenyon, K. R. Abrams, C. Mayne, P. Toozs-hobson et al., Botulinum Toxin A Versus Placebo for Refractory Detrusor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study), Eur Urol. 1 sept, vol.62, issue.3, pp.507-521, 2012.

R. K. Owen, K. R. Abrams, C. Mayne, M. Slack, and D. G. Tincello, Comparison of the effectiveness of repeated injections of onabotulinum toxin A for refractory idiopathic detrusor overactivity: analysis of an open label extension of a randomized trial (the RELAX study), Neurourol Urodyn. avr, vol.36, issue.4, pp.1201-1208, 2017.

A. Sahai, M. S. Khan, and P. Dasgupta, Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial, J Urol. 1 juin, vol.177, issue.6, pp.2231-2237, 2007.

A. Sahai, C. Dowson, M. S. Khan, and P. Dasgupta, Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial, BJU Int, vol.103, issue.11, pp.1509-1524, 2009.

A. Sahai, C. Dowson, M. S. Khan, and P. Dasgupta, Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity, Urology. 1 mars, vol.75, issue.3, pp.552-560, 2010.

W. Altaweel, A. Mokhtar, and D. M. Rabah, Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder, Urol Ann, vol.3, issue.2, pp.66-70, 2011.

M. K. Flynn, C. L. Amundsen, M. Perevich, F. Liu, and G. D. Webster, Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder, J Urol. juin, vol.181, issue.6, pp.2608-2623, 2009.

H. Kuo, Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics, Neurourol Urodyn, vol.30, issue.7, pp.1242-1250, 2011.

C. Liao, S. Chen, and H. Kuo, Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study, Neurourol Urodyn, vol.35, issue.6, pp.717-740, 2016.

O. Abdelwahab, H. Sherif, T. Soliman, I. Elbarky, and A. Eshazly, Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder, Int Braz J Urol Off J Braz Soc Urol, vol.41, issue.6, pp.1132-1172, 2015.

B. L. Cohen, P. Barboglio, D. Rodriguez, and A. E. Gousse, Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units, Neurourol Urodyn, vol.28, issue.3, pp.205-213, 2009.

R. Granese, G. Adile, G. Gugliotta, G. Cucinella, S. Saitta et al., Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection, Arch Gynecol Obstet, vol.286, issue.4, pp.923-932, 2012.

P. Miotla, R. Cartwright, K. Skorupska, M. Bogusiewicz, E. Markut-miotla et al., Urinary retention in female OAB after intravesical Botox injection: who is really at risk?, Int Urogynecology J. 1 juin, vol.28, issue.6, pp.845-50, 2017.

M. Werner, D. M. Schmid, and B. Schüssler, Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study, Am J Obstet Gynecol. mai, vol.192, issue.5, pp.1735-1775, 2005.

H. Kuo, Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics, Urology. juill, vol.66, issue.1, pp.94-102, 2005.

H. Kuo, C. Liao, and C. , Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome, Eur Urol. déc, vol.58, issue.6, pp.919-945, 2010.

C. Liao and H. Kuo, Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity, J Urol. mai, vol.189, issue.5, pp.1804-1814, 2013.

G. Amarenco, A. Guinet, M. Jousse, D. Verollet, and S. S. Ismael, Pencil and paper test: a new tool to predict the ability of neurological patients to practice clean intermittent self-catheterization, J Urol. févr, vol.185, issue.2, pp.578-82, 2011.

F. R. Tamburro, P. Castellan, F. Neri, F. Berardinelli, M. Bada et al., Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience, Urologia. nov, vol.85, issue.4, pp.163-171, 2018.

S. Khan, T. M. Kessler, A. Apostolidis, V. Kalsi, J. Panicker et al., What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection, J Urol. 1 avr, vol.181, issue.4, pp.1773-1781, 2009.

T. M. Kessler, S. Khan, J. Panicker, A. Roosen, S. Elneil et al., Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life, Obstet Gynecol. mai, vol.113, issue.5, pp.1046-51, 2009.

C. Dowson, J. Watkins, M. S. Khan, P. Dasgupta, and A. Sahai, Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates, Eur Urol. 1 avr, vol.61, issue.4, pp.834-843, 2012.

T. Marcelissen, &. Rahnama, . Ms, A. Snijkers, B. Schurch et al., Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms, World J Urol. 1 févr, vol.35, issue.2, pp.307-318, 2017.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

X. Deffieux, B. Fatton, P. Denys, E. Chartier-kastler, G. Amarenco et al., Injections intradétrusoriennes de toxine botulinique pour l'hyperactivité vésicale idiopathique réfractaire de la femme, J Gynécologie Obstétrique Biol Reprod, vol.43, issue.8, pp.572-80, 2014.

J. Houman, A. Moradzadeh, D. N. Patel, K. Asanad, J. T. Anger et al., What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens, Int Urogynecology J. mai, vol.30, issue.5, pp.701-705, 2019.

A. W. Stamm, S. A. Adelstein, A. Chen, A. Lucioni, K. C. Kobashi et al., Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review, J Urol, vol.200, issue.4, pp.809-823, 2018.

Y. Chen and H. Kuo, Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity, Low Urin Tract Symptoms. janv, vol.4, issue.1, pp.29-34, 2012.

R. M. Bauer, C. Gratzke, A. Roosen, Y. Hocaoglu, M. E. Mayer et al., Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome, Urol Int, vol.86, issue.1, pp.68-72, 2011.

A. Mohee, A. Khan, N. Harris, and I. Eardley, Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB), BJU Int, vol.111, issue.1, pp.106-119, 2013.

R. Veeratterapillay, C. Harding, L. Teo, N. Vasdev, A. Abroaf et al., Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity, Int J Urol, vol.21, issue.2, pp.175-183, 2014.

M. A. Avallone, B. S. Sack, A. El-arabi, M. L. Guralnick, O. Connor et al., Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity, Neurourol Urodyn, vol.36, issue.4, pp.1104-1111, 2017.

H. Kuo, Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity, J Urol, vol.178, issue.4, pp.1359-63, 2007.

R. P. Manecksha, I. M. Cullen, S. Ahmad, G. Mcneill, R. Flynn et al., Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity, Eur Urol. mai, vol.61, issue.5, pp.928-963, 2012.

G. Karsenty, E. Elzayat, T. Delapparent, B. St-denis, M. Lemieux et al., Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux, J Urol. mars, vol.177, issue.3, pp.1011-1015, 2007.

I. Makovey, T. Davis, M. L. Guralnick, O. Connor, and R. C. , Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability, Neurourol Urodyn, vol.30, issue.8, pp.1538-1578, 2011.

S. Lemière, D. Bruley, and S. Varannes, Pharmacologic actions and therapeutic importance of botulinum toxin in digestive diseases

, Gastroenterol Clin Biol. févr, vol.23, issue.2, pp.229-266, 1999.

G. Borodic, L. B. Pearce, and J. E. , Antibodies to botulinum toxin, Ophthalmology. juill, vol.101, issue.7, pp.1158-1167, 1994.

A. Apostolidis, P. Dasgupta, P. Denys, S. Elneil, C. J. Fowler et al., Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report, Eur Urol. 1 janv, vol.55, issue.1, pp.100-120, 2009.

A. Sahai, M. S. Khan, L. Gall, N. Dasgupta, and P. , Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder, Urology. 1 mars, vol.71, issue.3, pp.455-464, 2008.

D. M. Schmid, P. Sauermann, M. Werner, B. Schuessler, N. Blick et al., Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to Anticholinergics, J Urol. 1 juill, vol.176, issue.1, pp.177-85, 2006.

P. Kanagarajah, R. Ayyathurai, D. J. Caruso, C. Gomez, and A. E. Gousse, Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity, Int Urol Nephrol. févr, vol.44, issue.1, pp.91-98, 2012.

P. Ravindra, B. L. Jackson, and R. J. Parkinson, Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?, BJU Int. juill, vol.112, issue.1, pp.94-103, 2013.

Y. Cui, X. Zhou, H. Zong, H. Yan, and Y. Zhang, The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis, Neurourol Urodyn, vol.34, issue.5, pp.413-422, 2015.

, Annexe, vol.3

, Entourez les numéros qui correspondent à ce que vous ressentez (sautez les intitulés qui ne vous concernent pas

, Avant l'opération, lors des visites avec l'anesthésiste

, reçu de l'information sur ce qui allait se passer 2. J'ai pu poser les questions que je voulais 3. Je me suis sentie rassurée, détendue

, Avant l'opération, lors des visites avec le chirurgien

J. , information sur ce qui allait se passer 5. Je me suis sentie rassurée, détendue, mise en confiance A l'arrivée au bloc ou en salle d'intervention : 6. Mon intimité a été respectée Pendant l'intervention : 7. J'ai ressenti des sensations désagréables comme : soif, faim, nausées, vomissements

J. , entendre et/ou voir ce qui se passait Après l'intervention : 9. J'ai ressenti des sensations désagréables comme : soif, faim, nausées, vomissements

J. Dans-mon and . Confort, froid, chaud, mal installée sur le lit? 11. J'ai eu mal Depuis mon retour dans le service ou chez moi : 12. J'ai ressenti des sensations désagréables comme : soif, faim, nausées, vomissements

J. Dans-mon and . Confort,

, En salle de réveil, les médecins et le personnel soignant ont été attentionnés

, Depuis mon retour dans le service, le personnel soignant a été attentionné Les délais d'attente m'ont paru anormalement élevés : 18. Pour avoir un rendez-vous avec l'anesthésiste ou le chirurgien 19

, Si vous estimez, après nous avoir contactés, que vos droits Informatique et Libertés ne sont pas respectés ou que le dispositif de contrôle d'accès n'est pas conforme aux règles de protection des données, vous pouvez adresser une réclamation auprès de la CNIL par courrier

, Par ailleurs, vous pourrez être tenu informé des résultats globaux de cette recherche à la fin de l'étude

, Lorsque vous aurez lu cette note d'information et obtenu les réponses aux questions que vous vous posez en interrogeant le médecin investigateur, il vous sera proposé, si vous en êtes d'accord

A. U. Partie-reservee and . Medecin,

_. Le and . __, Après un temps de réflexion adéquat

, La patiente répond parfaitement aux critères d'éligibilité. N° d'inclusion : _______________ Nom et Signature du médecin : Annexe 6 : Pencil and Paper Test

, J Urol, vol.185, issue.2, pp.578-82, 2010.

G. Amarenco, A. Guinet, M. Jousse, D. Verollet, and S. S. Ismael, Service de Neuro-Urologie et d'Explorations Périnéales, APHP, Unité UMRS 731 UPMC

T. Médecine, , 2019.

, dont la prévalence augmente avec l'âge. C'est un sujet de santé publique ayant un impact sur le bienêtre physique et psychique des patientes, engageant des coûts directs et indirects pour la société. Les recommandations par consensus d'experts établies en 2013 préconisent une dose de 100U lors d'une première injection de Botox®, alors que l'AMM du produit fait initier le traitement à la dose de 50U, avec la possibilité d'augmenter cette dose à 100U pour les injections suivantes en cas de bonne tolérance

, Afin d'évaluer la satisfaction de nos patientes et dans le but d'homogénéiser nos pratiques, nous avons mis en place un protocole d'étude prospective dont l'objectif principal est d'évaluer l'efficacité de l'injection intradétrusorienne de toxine botulique de type A à la dose de 50U à 6 semaines par la variation du score de qualité de

, Notre protocole a été validé par les différents comités d'éthique (COMVAL, CPP, CNIL), il est enregistré dans la base de données clinicaltrials.gov, et nous avons récemment débuté les inclusions. MOTS-CLES Hyperactivité vésicale idiopathique ; Botox ; Onabotulinum toxinA ; 50 unités, Les objectifs secondaires visent à évaluer la qualité de vie à 2, 6 et 12 semaines par le questionnaire USP (Urinary Symptom Profile), vol.30, 2019.